Maktaba

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

Authors : Wang DS; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.; Ren C

Subjects: Cetuximab*/Cetuximab*/Cetuximab*/administration & dosage ; Cetuximab*/Cetuximab*/Cetuximab*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use FOLFOXIRI protocol; Folfox protocol

Source: PLoS medicine [PLoS Med] 2024 May 10; Vol. 21 (5), pp. e1004389. Date of Electronic Publication: 2024 May 10 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Academic Journal

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.

Authors : Zhang Y; Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, 330006, P.R. of China.; Jiangxi Key Laboratory of Clinical and Translational Cancer Research, Nanchang, 330006, P.R. of China.

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/pathology ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/mortality

Source: World journal of surgical oncology [World J Surg Oncol] 2024 May 06; Vol. 22 (1), pp. 122. Date of Electronic Publication: 2024 May 06.Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819

Record details

Read Online Read More Add to Saved list

Academic Journal

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.

Authors : Kato K; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Doki Y

Subjects: Ipilimumab*/Ipilimumab*/Ipilimumab*/administration & dosage ; Ipilimumab*/Ipilimumab*/Ipilimumab*/therapeutic use ; Ipilimumab*/Ipilimumab*/Ipilimumab*/adverse effects

Source: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7235.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.

Authors : Qiao L; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Centre, Guangzhou, China.; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/mortality ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/therapy

Source: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7236.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.

Authors : Yu TT; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.; Hu X

Subjects: Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/drug therapy ; Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/mortality ; Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/radiotherapy

Source: Cancer medicine [Cancer Med] 2024 Apr; Vol. 13 (8), pp. e7215.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Long-term Musculoskeletal Consequences of Chemotherapy in Pediatric Mice.

Authors : Huot JR; Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, 46202 USA.; Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202 USA.

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects; Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives; Animals IFL protocol

Source: Function (Oxford, England) [Function (Oxf)] 2024 Mar 07; Vol. 5 (3), pp. zqae011. Date of Electronic Publication: 2024 Mar 07 (Print Publication: 2024).Publisher: Oxford University Press Country of Publication: England NLM ID: 101770668 Publication Model: eCollection Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Comparison of efficacy of neoadjuvant chemotherapy with gemcitabine plus cisplatin versus docetaxil, cisplatin, plus fluorouracil in locally advanced nasopharyngeal carcinoma.

Authors : Rehman A; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan.; Haider G

Subjects: Cisplatin*/Cisplatin*/Cisplatin*/administration & dosage ; Cisplatin*/Cisplatin*/Cisplatin*/therapeutic use ; Gemcitabine*

Source: Pakistan journal of pharmaceutical sciences [Pak J Pharm Sci] 2024 Mar; Vol. 37 (2), pp. 377-383.Publisher: Faculty of Pharmacy, University of Karachi Country of Publication: Pakistan NLM ID: 9426356 Publication Model: Print Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Academic Journal

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.

Authors : Wimmer K; Department of General Surgery, Division of Visceral Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/pharmacology ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/pathology

Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Nov 14; Vol. 42 (1), pp. 300. Date of Electronic Publication: 2023 Nov 14.Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966

Record details

Read Online Read More Add to Saved list

Academic Journal

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.

Authors : Fukahori M; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume-Shi, Fukuoka, 830-0011, Japan.; Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-Ku, Kyoto, 606-8507, Japan.

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapy; Humans

Source: Scientific reports [Sci Rep] 2023 Nov 08; Vol. 13 (1), pp. 19399. Date of Electronic Publication: 2023 Nov 08.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.

Authors : Belhabri A; Department of Hematology, Leon Berard Cancer Center, Lyon, France.; Heiblig M

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/diagnosis ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy

Source: Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (16), pp. 16929-16944. Date of Electronic Publication: 2023 Aug 07.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.

Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.

Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.

Long-term Musculoskeletal Consequences of Chemotherapy in Pediatric Mice.

Comparison of efficacy of neoadjuvant chemotherapy with gemcitabine plus cisplatin versus docetaxil, cisplatin, plus fluorouracil in locally advanced nasopharyngeal carcinoma.

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.

Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.